CLINICAL STUDIES
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin
Systematic overview of individual data from 96,712 randomized patients
Roberto Latini, MD*,
Gianni Tognoni, MD*,
Aldo P. Maggioni, MD*  ,
Colin Baigent, MB, BCh ,
Eugene Braunwald, MD ,
Zheng-Ming Chen, PhD,
Rory Collins, MB, BS,
Marcus Flather, MD||,
MariaGrazia Franzosi, PhD*,
John Kjekshus, MD¶,
Lars Køber, MD#,
Li-Sheng Liu, MD**,
Richard Peto, FRS,
Marc Pfeffer, MD,
Fabrizio Pizzetti, MD,
Eugenio Santoro, MSc*,
Peter Sleight, MD,
Karl Swedberg, MD,
Luigi Tavazzi, MD,
Wen Wang, MSc**,
Salim Yusuf, MD|||| on behalf of the Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group1
* Istituto di Ricerche Farmacologiche "Mario Negri," Milano, Italy
Associazione Nazionale Medici-Cardiologi Ospedalieri, Firenze, Italy
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, United Kingdom
Brigham and Women’s Hospital, Boston, Massachusetts, USA
|| Royal Brompton Hospital, London, United Kingdom
¶ The National Hospital, University of Oslo, Oslo, Norway
# Gentofte Hospital/University of Copenhagen, Hellerup, Denmark
** Fu Wai Hospital, Beijing, China
Santo Spirito Hospital, Casale Monferrato (AL), Italy
Göteborg University, Göteborg, Sweden
Policlinico S. Matteo, Pavia, Italy
|||| McMaster Clinic, Hamilton General Hospital, Hamilton, Ontario, Canada
Manuscript received November 16, 1998;
revised manuscript received December 16, 1999,
accepted February 9, 2000.
Reprint requests and correspondence: Dr. Roberto Latini, Department of Cardiovascular Research, Istituto Mario Negri, Via Eritrea, 62, 20157 Milano, Italy
latini{at}irfmn.mnegri.it
OBJECTIVES
We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA).
BACKGROUND
Aspirin and ACEi both reduce mortality when given early after MI. Aspirin inhibits the synthesis of vasodilating prostaglandins, and, in principle, this inhibition might antagonize some of the effects of ACEi. But it is uncertain whether, in practice, this influences the effects of ACEi on mortality and major morbidity after MI.
METHODS
This overview sought individual patient data from all trials involving more than 1,000 patients randomly allocated to receive ACEi or control starting in the acute phase of MI (0–36 h from onset) and continuing for four to six weeks. Data on concomitant ASA use were available for 96,712 of 98,496 patients in four eligible trials (and for none of 1,556 patients in the one other eligible trial).
RESULTS
Overall 30-day mortality was 7.1% among patients allocated to ACEi and 7.6% among those allocated to control, corresponding to a 7% (standard deviation [SD], 2%) proportional reduction (95% confidence interval 2% to 11%, p = 0.004). Angiotensin-converting enzyme inhibitor was associated with similar proportional reductions in 30-day mortality among the 86,484 patients who were taking ASA (6% [SD, 3%] reduction) and among the 10,228 patients who were not (10% [SD, 5%] reduction: chi-squared test of heterogeneity between these reductions = 0.4; p = 0.5). Angiotensin-converting enzyme inhibitor produced definite increases in the incidence of persistent hypotension (17.9% ACEi vs. 9.4% control) and of renal dysfunction (1.3% ACEi vs. 0.6% control), but there was no good evidence that these effects were different in the presence or absence of ASA (chi-squared for heterogeneity = 0.4 and 0.0, respectively; both not significant). Nor was there good evidence that the effects of ACEi on other clinical outcomes were changed by concomitant ASA use.
CONCLUSIONS
Both ASA and ACEi are beneficial in acute MI. The present results support the early use of ACEi in acute MI, irrespective of whether or not ASA is being given.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | ACEi | = angiotensin-converting enzyme inhibitor | | ASA | = aspirin | | CCS | = Chinese Cardiac Study | | CONSENSUS | = Cooperative New Scandinavian Enalapril Survival Study | | GISSI | = Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico | | ISIS | = International Study of Infarct Survival | | MI | = myocardial infarction | | SD | = standard deviation | | SOLVD | = Studies Of Left Ventricular Dysfunction |
|
This article has been cited by other articles:
|
|
|
|
 
C. Patrono, C. Baigent, J. Hirsh, and G. Roth
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
199S - 233S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goyal, J. H. Alexander, G. E. Hafley, S. H. Graham, R. H. Mehta, M. J. Mack, R. K. Wolf, L. H. Cohn, N. T. Kouchoukos, R. A. Harrington, et al.
Outcomes Associated With the Use of Secondary Prevention Medications After Coronary Artery Bypass Graft Surgery
Ann. Thorac. Surg.,
March 1, 2007;
83(3):
993 - 1001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nakashima, T. Katayama, C. Takagi, K. Amenomori, M. Ishizaki, Y. Honda, and S. Suzuki
Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction
Eur. Heart J.,
October 1, 2006;
27(19):
2317 - 2322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Jhund and J. J.V. McMurray
Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis
Circulation,
June 6, 2006;
113(22):
2566 - 2568.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. A. McAlister, W. A. Ghali, Y. Gong, J. Fang, P. W. Armstrong, and J. V. Tu
Aspirin Use and Outcomes in a Community-Based Cohort of 7352 Patients Discharged After First Hospitalization for Heart Failure
Circulation,
June 6, 2006;
113(22):
2572 - 2578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Part 8: Stabilization of the Patient With Acute Coronary Syndromes
Circulation,
December 13, 2005;
112(24_suppl):
IV-89 - IV-110.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I Gemmell, R F Heller, P McElduff, K Payne, G Butler, R Edwards, M Roland, and P Durrington
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease
J Epidemiol Community Health,
December 1, 2005;
59(12):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent
Low-dose aspirin for the prevention of atherothrombosis.
N. Engl. J. Med.,
December 1, 2005;
353(22):
2373 - 2383.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Part 5: Acute Coronary Syndromes
Circulation,
November 29, 2005;
112(22_suppl):
III-55 - III-72.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.A. Chacko
Cardiac Medical Therapy Following Coronary Artery Bypass Graft Surgery
J. Am. Coll. Cardiol.,
September 6, 2005;
46(5):
934 - 934.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C Simmonds, J. P T Higginsa, L. A Stewartb, J. F Tierneyb, M. J Clarke, and S. G Thompson
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice
Clinical Trials,
June 1, 2005;
2(3):
209 - 217.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Weir and J J V McMurray
Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction
Heart,
May 1, 2005;
91(suppl_2):
ii17 - ii20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Endorsed by the European Society of Intensive Care, Authors/Task Force Members, M. S. Nieminen, M. Bohm, M. R. Cowie, H. Drexler, G. S. Filippatos, G. Jondeau, Y. Hasin, J. Lopez-Sendon, et al.
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology
Eur. Heart J.,
February 2, 2005;
26(4):
384 - 416.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau
Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?
Circulation,
November 16, 2004;
110(20):
3281 - 3288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
234S - 264S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci
Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial
Diabetes Care,
December 1, 2003;
26(12):
3264 - 3272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Brunner-La Rocca
Interaction of Angiotensin-Converting Enzyme Inhibition and Aspirin in Congestive Heart Failure: Long Controversy Finally Resolved?
Chest,
October 1, 2003;
124(4):
1192 - 1194.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Aumegeat, N. Lamblin, P. de Groote, E. P. Mc Fadden, A. Millaire, C. Bauters, and J.-M. Lablanche
Aspirin Does Not Adversely Affect Survival in Patients With Stable Congestive Heart Failure Treated With Angiotensin-Converting Enzyme Inhibitors
Chest,
October 1, 2003;
124(4):
1250 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Meune, J.-J. Mourad, J.-F. Bergmann, and C. Spaulding
Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance
Journal of Renin-Angiotensin-Aldosterone System,
September 1, 2003;
4(3):
149 - 154.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. J. Velazquez, M. A. Pfeffer, J. V. McMurray, A. P. Maggioni, J.-L. Rouleau, F. Van de Werf, L. Kober, H. D. White, K. Swedberg, J. D. Leimberger, et al.
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
Eur J Heart Fail,
August 1, 2003;
5(4):
537 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Guazzi, R. Brambilla, G. Reina, G. Tumminello, and M. D. Guazzi
Aspirin-Angiotensin-Converting Enzyme Inhibitor Coadministration and Mortality in Patients With Heart Failure: A Dose-Related Adverse Effect of Aspirin
Arch Intern Med,
July 14, 2003;
163(13):
1574 - 1579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Lapointe, Q. T. Nguyen, J.-F. Desjardins, F. Marcotte, A. Pourdjabbar, G. Moe, A. Calderone, and J.-L. Rouleau
Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling
Am J Physiol Heart Circ Physiol,
June 5, 2003;
285(1):
H398 - H405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B.-q. Zhu, R. E Sievers, A. E. Browne, R. J Lee, K. Chatterjee, W. Grossman, J. S Karliner, and W. W Parmley
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function
Journal of Renin-Angiotensin-Aldosterone System,
March 1, 2003;
4(1):
31 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K Dubey, D K Balani, and K K Pillai
Potential adverse interaction between aspirin and Lisinopril in hypertensive rats
Human and Experimental Toxicology,
March 1, 2003;
22(3):
143 - 147.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G.M. Carville, K. E. Guyer, and E. R. Bates
Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction
Circulation,
January 7, 2003;
107(1):
32 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Califf and D. L. DeMets
Principles From Clinical Trials Relevant to Clinical Practice: Part I
Circulation,
August 20, 2002;
106(8):
1015 - 1021.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lauer
Aspirin for Primary Prevention of Coronary Events
N. Engl. J. Med.,
May 9, 2002;
346(19):
1468 - 1474.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. McMurray and M. A. Pfeffer
New Therapeutic Options in Congestive Heart Failure: Part II
Circulation,
May 7, 2002;
105(18):
2223 - 2228.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Lazar, Y. Bao, S. Rivers, and S. A. Bernard
Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury
Ann. Thorac. Surg.,
May 1, 2002;
73(5):
1522 - 1527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lindenfeld, A. D. Robertson, B. D. Lowes, M. R. Bristow, and for the MOCHA Investigators
Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers
J. Am. Coll. Cardiol.,
December 1, 2001;
38(7):
1950 - 1956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Baigent, R. Collins, and R. Peto
Benefit of aspirin plus angiotensin-converting enzyme inhibitor
J. Am. Coll. Cardiol.,
April 1, 2001;
37(5):
1474 - 1475.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hall
Benefit of aspirin plus angiotensin-converting enzyme inhibitor: reply
J. Am. Coll. Cardiol.,
April 1, 2001;
37(5):
1475 - 1475.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
J. Am. Coll. Cardiol.,
January 1, 2001;
37(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth
Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects
Chest,
January 1, 2001;
119
(2009):
39S - 63S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hall
The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not
J. Am. Coll. Cardiol.,
June 1, 2000;
35(7):
1808 - 1812.
[Full Text]
[PDF]
|
|
|
|
